中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
16期
98-99
,共2页
左卡尼汀%稳心颗粒%不稳定型心绞痛
左卡尼汀%穩心顆粒%不穩定型心絞痛
좌잡니정%은심과립%불은정형심교통
L - carnitine%Wenxin Granules%unstable angina pectoris(UAP)
目的：探讨左卡尼汀联合稳心颗粒治疗不稳定型心绞痛（UAP）的效果。方法90例 UAP 患者按入院先后顺序随机分为观察组和对照组，每组45例。两组患者均给予西医常规治疗，观察组在此基础上加用左卡尼汀和稳心颗粒。结果观察组总有效率为95.56%(43/45)，对照组为77.78%(35/45)，差异有统计学意义（χ2=6.15，P <0.05）。两组治疗后心绞痛积分及高敏 C 反应蛋白（hs - CRP）均显著降低（ P <0.05），且观察组显著低于对照组（ P <0.05）。两组均未见明显不良反应。结论左卡尼汀联合稳心颗粒能有效改善UAP 症状，标本同治兼顾，安全指数高，值得临床推广。
目的：探討左卡尼汀聯閤穩心顆粒治療不穩定型心絞痛（UAP）的效果。方法90例 UAP 患者按入院先後順序隨機分為觀察組和對照組，每組45例。兩組患者均給予西醫常規治療，觀察組在此基礎上加用左卡尼汀和穩心顆粒。結果觀察組總有效率為95.56%(43/45)，對照組為77.78%(35/45)，差異有統計學意義（χ2=6.15，P <0.05）。兩組治療後心絞痛積分及高敏 C 反應蛋白（hs - CRP）均顯著降低（ P <0.05），且觀察組顯著低于對照組（ P <0.05）。兩組均未見明顯不良反應。結論左卡尼汀聯閤穩心顆粒能有效改善UAP 癥狀，標本同治兼顧，安全指數高，值得臨床推廣。
목적：탐토좌잡니정연합은심과립치료불은정형심교통（UAP）적효과。방법90례 UAP 환자안입원선후순서수궤분위관찰조화대조조，매조45례。량조환자균급여서의상규치료，관찰조재차기출상가용좌잡니정화은심과립。결과관찰조총유효솔위95.56%(43/45)，대조조위77.78%(35/45)，차이유통계학의의（χ2=6.15，P <0.05）。량조치료후심교통적분급고민 C 반응단백（hs - CRP）균현저강저（ P <0.05），차관찰조현저저우대조조（ P <0.05）。량조균미견명현불량반응。결론좌잡니정연합은심과립능유효개선UAP 증상，표본동치겸고，안전지수고，치득림상추엄。
Objective To investigate the effect of L - carnitine combined with Wenxin Granules in treating unstable angina pectoris (UAP). Methods 90 cases of UAP were randomly divided into the observation and the control group according to the order of hospital admission,45 cases in each group. Both of the two groups were given the Western medicine routine treatment,on this basis the obser-vation group was added with L - carnitine and Wenxin Granules. Results The total effective rate of the observation group was 95. 56%(43 / 45) and which of the control group was 77. 78% (35 / 45)% ,the difference was statistically significant( χ2 = 6. 15,P < 0. 05). After treatment,the angina scores and hs - CRP in the two groups were significantly decreased( P < 0. 05),moreover the observation group was significantly lower than the control group( P < 0. 05). No obvious adverse reactions occurred in the two groups. Conclusion L - carnitine combined with Wenxin Granules can effectively improve the symptoms of UAP with high security index and is worthy of clinical promotion and application.
